4/11
05:32 am
inbx
Inhibrx Biosciences (INBX) was upgraded by Zacks Research to "hold".
Medium
Report
Inhibrx Biosciences (INBX) was upgraded by Zacks Research to "hold".
4/11
01:00 am
inbx
Medium
Report
4/8
08:03 am
inbx
Inhibrx Biosciences (INBX) is now covered by Stifel Nicolaus. They set a "buy" rating and a $150.00 price target on the stock.
Low
Report
Inhibrx Biosciences (INBX) is now covered by Stifel Nicolaus. They set a "buy" rating and a $150.00 price target on the stock.
3/19
04:36 pm
inbx
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results [Yahoo! Finance]
3/19
04:10 pm
inbx
Inhibrx Biosciences GAAP EPS of -$2.11 misses by $0.03 [Seeking Alpha]
Medium
Report
Inhibrx Biosciences GAAP EPS of -$2.11 misses by $0.03 [Seeking Alpha]
3/19
04:00 pm
inbx
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Medium
Report
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
3/2
04:13 pm
inbx
Inhibrx Announces Participation in Upcoming Scientific Conference [Yahoo! Finance]
Medium
Report
Inhibrx Announces Participation in Upcoming Scientific Conference [Yahoo! Finance]
3/2
04:00 pm
inbx
Inhibrx Announces Participation in Upcoming Scientific Conference
Medium
Report
Inhibrx Announces Participation in Upcoming Scientific Conference
2/26
05:47 pm
inbx
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight [Yahoo! Finance]
Medium
Report
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight [Yahoo! Finance]
1/24
05:08 am
inbx
Inhibrx Biosciences (NASDAQ:INBX) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Inhibrx Biosciences (NASDAQ:INBX) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.